Beyond the 'Healthy Carrier': When Genotype Demands Functional Confirmation

Background: The label "carrier" implies that a patient with a single pathogenic variant remains unaffected because the normal allele provides sufficient function. However, symptomatic heterozygotes are increasingly recognized in hematologic, metabolic, and immunologic disorders. We present two paediatric cases in which the "healthy carrier" label proved misleading, and functional testing clarified the genotype–phenotype relationship.

Cases and Results: An 8-year-old boy presented with recurrent epistaxis, later found to have persistent hepatosplenomegaly and hypergammaglobulinemia. Initial genetic testing revealed one pathogenic GBA1 variant and one pathogenic IFIH1 variant, labelling him a carrier for both. Targeted PCR and enzymatic testing detected a second GBA1 variant with deficient enzyme activity, establishing Gaucher disease type 1. IFIH1 gain-of-function is linked to systemic autoimmunity within the type I interferonopathy spectrum and to features overlapping Gaucher disease (hepatosplenomegaly, osteopenia, short stature), reframing this variant as clinically relevant.

A 12-year-old girl presented with recurrent severe allergic reactions (angioedema, allergoderma), pericarditis, and atrial and ventricular septal defects. Genetic testing revealed a pathogenic G6PD variant, labelling her a carrier. Enzymatic testing demonstrated deficient glucose-6-phosphate dehydrogenase activity, reported in association with septal defects and immune dysregulation.

Conclusion: A "healthy carrier" result is not synonymous with an unaffected individual. In both patients, functional and molecular testing revealed clinical relevance: enzyme assay confirmed G6PD deficiency in a heterozygous girl, while targeted PCR and enzymatic testing identified biallelic GBA1 disease and helped reframe an IFIH1 variant. Carrier labels warrant functional confirmation rather than reassurance.